Quarterly ResultAug 6, 2026, 04:22 PM
Alector Q2 Net Loss $23.0M; Cash $172.8M, Runway Through 2027
AI Summary
Alector, Inc. reported a net loss of $23.0 million, or $0.21 per share, for the second quarter ended June 30, 2026, with collaboration revenue of $3.3 million. The company ended the quarter with $172.8 million in cash, cash equivalents, and investments, which is expected to fund operations at least through 2027. Alector also provided updates on its Alector Brain Carrier (ABC) platform, including AL137, its lead anti-amyloid beta antibody program for Alzheimer’s disease, targeting an IND submission in Q1 2027 and first-in-human dosing by April 2027. Progress continues on its ABC-enabled siRNA platform and AL050 for Parkinson's disease.
Key Highlights
- Cash, cash equivalents, and investments totaled $172.8 million as of June 30, 2026.
- Management anticipates cash runway at least through 2027.
- Q2 2026 net loss was $23.0 million, or $0.21 net loss per share.
- Q2 2026 collaboration revenue was $3.3 million.
- Q2 2026 R&D expenses decreased to $19.5 million.
- Q2 2026 G&A expenses decreased to $8.3 million.
- AL137, lead anti-amyloid beta antibody, targets IND submission in Q1 2027.
- First-in-human dosing for AL137 is targeted no later than April 2027.
Price Impact
More from ALEC